9 research outputs found
Non-invasive muscle contraction assay to study rodent models of sarcopenia
<p>Abstract</p> <p>Background</p> <p>Age-related sarcopenia is a disease state of loss of muscle mass and strength that affects physical function and mobility leading to falls, fractures, and disability. The need for therapies to treat age-related sarcopenia has attracted intensive preclinical research. To facilitate the discovery of these therapies, we have developed a non-invasive rat muscle functional assay system to efficiently measure muscle force and evaluate the efficacy of drug candidates.</p> <p>Methods</p> <p>The lower leg muscles of anesthetized rats are artificially stimulated with surface electrodes on the knee holders and the heel support, causing the lower leg muscles to push isometric pedals that are attached to force transducers. We developed a stimulation protocol to perform a fatigability test that reveals functional muscle parameters like maximal force, the rate of fatigue, fatigue-resistant force, as well as a fatigable muscle force index. The system is evaluated in a rat aging model and a rat glucocorticoid-induced muscle loss model</p> <p>Results</p> <p>The aged rats were generally weaker than adult rats and showed a greater reduction in their fatigable force when compared to their fatigue-resistant force. Glucocorticoid treated rats mostly lost fatigable force and fatigued at a higher rate, indicating reduced force from glycolytic fibers with reduced energy reserves.</p> <p>Conclusions</p> <p>The involuntary contraction assay is a reliable system to assess muscle function in rodents and can be applied in preclinical research, including age-related sarcopenia and other myopathy.</p
QOL-12. SPORTS FOR ALL – MOTIVATING NEURO-ONCOLOGY PATIENTS TO ENGAGE IN SPORTING ACTIVITY
Exploring the Role of ‘Shadowing’ as a Beneficial Preparatory Step for Sensitive Qualitative Research with Children and Young People with Serious Health Conditions
Determination of in Vivo Enzyme Occupancy Utilizing Inhibitor Dissociation Kinetics
During drug discovery, assessment
of in vivo target occupancy by therapeutic candidates is often required
for predicting clinical efficacy. Current strategies for determining
target occupancy include using radiolabeled or irreversible surrogates,
which can be technically challenging, and the results are often not
sufficiently quantitative. We developed a straightforward method by
applying slow-dissociation kinetics to quantitatively determine enzyme
occupancy without using specialized reagents. We applied this method
to determine occupancy of Cathepsin K inhibitors in bone tissues harvested
from rabbit femurs. Tissues from dosed animals were harvested, flash
frozen, lysed, then analyzed by a jump-dilution assay with substrate.
The rate of substrate turnover was monitored continuously until reaching
steady state and progress curves were fit with the equation [product]
= <i>v</i><sub>s</sub><i>t</i> + ((<i>v</i><sub>i</sub> – <i>v</i><sub>s</sub>)/<i>k</i><sub>obs</sub>)(1 – exp(−<i>k</i><sub>obs</sub><i>t</i>)). The initial rate <i>v</i><sub><i>i</i></sub> represents the residual activity of the enzyme before
inhibitor dissociation; <i>v</i><sub>s</sub> is the reaction
rate after dissociation of the inhibitor. Occupancy is derived from
the ratio of <i>v</i><sub><i>i</i></sub>/<i>v</i><sub>s</sub>. A significant benefit of the method is that
data from both the occupied and unoccupied states are obtained in
the same assay under identical conditions, which provides greater
consistency between studies. The Cat K inhibitor MK-0674 (in vitro
IC<sub>50</sub> 1 nM) was tested in young rabbits (<6 month old)
and showed a dose-dependent increase in occupancy, reaching essentially
complete occupancy at 1.0 mg/kg. In addition the method enables measurement
of the total Cat K in the target tissue. Results confirmed complete
occupancy even as the osteoclasts responded to higher doses with increased
enzyme production
Graft-versus-host disease-associated angiomatosis: A clinicopathologically distinct entity
Validating a Proteomic Signature of Severe COVID-19
OBJECTIVES:. COVID-19 is a heterogenous disease. Biomarker-based approaches may identify patients at risk for severe disease, who may be more likely to benefit from specific therapies. Our objective was to identify and validate a plasma protein signature for severe COVID-19.
DESIGN:. Prospective observational cohort study.
SETTING:. Two hospitals in the United States.
PATIENTS:. One hundred sixty-seven hospitalized adults with COVID-19.
INTERVENTION:. None.
MEASUREMENTS AND MAIN RESULTS:. We measured 713 plasma proteins in 167 hospitalized patients with COVID-19 using a high-throughput platform. We classified patients as nonsevere versus severe COVID-19, defined as the need for high-flow nasal cannula, mechanical ventilation, extracorporeal membrane oxygenation, or death, at study entry and in 7-day intervals thereafter. We compared proteins measured at baseline between these two groups by logistic regression adjusting for age, sex, symptom duration, and comorbidities. We used lead proteins from dysregulated pathways as inputs for elastic net logistic regression to identify a parsimonious signature of severe disease and validated this signature in an external COVID-19 dataset. We tested whether the association between corticosteroid use and mortality varied by protein signature. One hundred ninety-four proteins were associated with severe COVID-19 at the time of hospital admission. Pathway analysis identified multiple pathways associated with inflammatory response and tissue repair programs. Elastic net logistic regression yielded a 14-protein signature that discriminated 90-day mortality in an external cohort with an area under the receiver-operator characteristic curve of 0.92 (95% CI, 0.88–0.95). Classifying patients based on the predicted risk from the signature identified a heterogeneous response to treatment with corticosteroids (p = 0.006).
CONCLUSIONS:. Inpatients with COVID-19 express heterogeneous patterns of plasma proteins. We propose a 14-protein signature of disease severity that may have value in developing precision medicine approaches for COVID-19 pneumonia
Large-scale migration into Britain during the Middle to Late Bronze Age
Present-day people from England and Wales harbour more ancestry derived from Early European Farmers (EEF) than people of the Early Bronze Age . To understand this, we generated genome-wide data from 793 individuals, increasing data from the Middle to Late Bronze and Iron Age in Britain by 12-fold, and Western and Central Europe by 3.5-fold. Between 1000 and 875 BC, EEF ancestry increased in southern Britain (England and Wales) but not northern Britain (Scotland) due to incorporation of migrants who arrived at this time and over previous centuries, and who were genetically most similar to ancient individuals from France. These migrants contributed about half the ancestry of Iron Age people of England and Wales, thereby creating a plausible vector for the spread of early Celtic languages into Britain. These patterns are part of a broader trend of EEF ancestry becoming more similar across central and western Europe in the Middle to Late Bronze Age, coincident with archaeological evidence of intensified cultural exchange . There was comparatively less gene flow from continental Europe during the Iron Age, and Britain's independent genetic trajectory is also reflected in the rise of the allele conferring lactase persistence to ~50% by this time compared to ~7% in central Europe where it rose rapidly in frequency only a millennium later. This suggests that dairy products were used in qualitatively different ways in Britain and in central Europe over this period. [Abstract copyright: © 2021. The Author(s), under exclusive licence to Springer Nature Limited.